Quantcast
Last updated on April 23, 2014 at 10:36 EDT

Latest Riociguat Stories

2014-03-10 08:22:19

-- Bayer's Adempas (riociguat tablets) approved for the treatment of pulmonary arterial hypertension (PAH)(1), which affects up to 2000 Canadians(2) -- Adempas provides novel and specific approach to treat different types of pulmonary hypertension (PH), a serious condition of the heart and lungs -- Only drug in Canada indicated to treat two rare types of PH - PAH and chronic thromboembolic pulmonary hypertension (CTEPH)(1,3) TORONTO, March...

2013-10-28 12:25:24

WHIPPANY, N.J., Oct. 28, 2013 /PRNewswire/ -- Bayer HealthCare today announced preliminary results from two ongoing, open-label, long-term extension studies investigating its recently approved Adempas(®) (riociguat) tablets will be presented in scientific forum at CHEST 2013, the annual meeting of the American College of Chest Physicians, October 26 - 31, in Chicago, IL. Adempas was approved by the United States Food and Drug Administration on October 8, 2013 for: (i) the treatment of...

2013-10-11 23:19:10

Only a handful of the 7,000 rare diseases in the US have more than one treatment, and most have none. Why have science and medicine grown so much in pulmonary hypertension, and how is the field addressing the next big challenge — early diagnosis? Silver Spring, MD (PRWEB) October 11, 2013 The US Food and Drug Administration yesterday approved the tenth treatment, riociguat, for pulmonary hypertension (PH), a rare and life-threatening lung disease affecting roughly 20-30,000 patients,...

2013-10-09 08:27:05

First and only drug approved in U.S. to Treat Two Forms of Pulmonary Hypertension (WHO Group 1 and 4) WHIPPANY, N.J., Oct. 9, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the United States Food and Drug Administration (FDA) has approved Adempas(®) (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO...

2013-10-08 20:22:34

First and only drug approved in U.S. to Treat Two Forms of Pulmonary Hypertension (WHO Group 1 and 4) WHIPPANY, N.J., Oct. 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the United States Food and Drug Administration (FDA) has approved Adempas(®) (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO...

2013-09-25 08:29:50

WHIPPANY, N.J., Sept. 25, 2013 /PRNewswire/ -- Bayer HealthCare today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted two separate orphan drug designations for its investigational, oral medication riociguat, proposed trade name Adempas(®), for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The Orphan Drug Designation program provides orphan status to...

2013-09-23 08:22:41

-- Adempas® (riociguat) offers new hope for patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) -- Adempas® is now available in Canada as the first and only drug indicated to manage the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)1,2 TORONTO, Sept. 23, 2013 /CNW/ - Bayer Inc. announced today the Health Canada approval of Adempas® (riociguat). Adempas® is the first drug...

2013-08-06 16:27:58

If approved by the FDA, riociguat will be the first treatment for inoperable CTEPH or persistent/recurrent CTEPH after surgery and a new treatment for PAH WHIPPANY, N.J., Aug. 6, 2013 /PRNewswire/ -- Bayer HealthCare today announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval for investigational riociguat, proposed trade name Adempas(TM), in two forms of pulmonary hypertension. The Committee voted 11 to 0...

2013-07-17 12:26:55

Payers are Most Receptive to Reimbursing Novel Therapies that Offer Clinical Improvements in Mean Pulmonary Arterial Pressure and Have Evidence of Utility in Multiple PAH Etiologies, According to a New Report from Decision Resources BURLINGTON, Mass., July 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed pulmonologists in the United States consider a drug's effect on...

2013-05-08 08:30:20

WAYNE, N.J., May 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American Thoracic Society (ATS) International Conference May 17 - 22, in Philadelphia, PA. "We are pleased that multiple new data sets from our riociguat clinical development program in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension were accepted for...